Skip to main content

Table 4 Univariate and multivariate Cox regression analysis of clinical characteristics and laboratory indicators on OS

From: COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study

Characteristic

Univariate analysis

Multivariate analysis

HR

CI 95%

p value

HR

CI 95%

p value

Age

1.019

0.991–1.048

0.190

   

Gender

1.247

0.585–2.658

0.570

   

Smoking

1.533

0.877–2.680

0.130

   

ECOG

2.322

1.308–4.123

0.004

2.026

0.971–4.227

0.050

Treatment line

1.680

0.967–2.919

0.066

   

Combined therapy

0.609

0.312–1.190

0.150

   

Stage

1.697

0.798–3.610

0.170

   

PD-(L)1

0.483

0.254–0.917

0.026

0.751

0.359–1.573

0.447

Vaccination

0.166

0.052–0.533

0.003

0.186

0.043–0.798

0.023

NLR

1.051

1.028–1.075

0.000

1.060

1.019–1.103

0.004

Albumin

0.880

0.839–0.924

0.000

0.937

0.877–1.001

0.053

D-D

1.017

0.970–1.066

0.480

   

CD3

0.986

0.952–1.019

0.380

   

CD4

0.988

0.957–1.020

0.470

   

CD8

1.005

0.971–1.039

0.790

   

CD4/CD8

1.053

0.733–1.512

0.780

   

CD56

1.019

0.983–1.056

0.300

   

CD19

0.997

0.939–1.059

0.930

   

IgM

0.634

0.203–1.978

0.430

   

IgA

1.137

0.719-1.800

0.580

   

IgG

1.027

0.948–1.114

0.510

   

IgE

1.000

0.999–1.001

0.500

   

Fibrinogen

1.397

1.138–1.717

0.001

1.301

0.971–1.742

0.070

  1. NLR Neutrophil-lymphocyte ratio; IgM Immunoglobulin M; IgG Immunoglobulin G; IgA Immunoglobulin A; IgE Immunoglobulin E; OS Overall survival
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us